. Mutations in tumour-suppressor genes, or in components of the pathways that activate them, enable continued cell proliferation but dysregulate DNA replication and repair, ultimately resulting in genome instability and the inexorable selection of an ever more aggressive malignancy 1, 3 . Host recognition of cancer cells via the immune system constitutes an independent line of defence based on the ability to identify and destroy tumour cells, which is defined as cancer immunosurveillance [4] [5] [6] [7] [8] . Recently, a number of studies have indicated that the immune system has a crucial role in regulating tumour development in non-virally induced tumours in addition to its long-established role in controlling tumours initiated by viruses 9, 10 . Accumulating evidence indicates that tumour-suppressor genes, and p53 (encoded by TP53) in particular, may act in response to a variety of cellular homeostatic stresses ranging from ribosomal to metabolic [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . It now seems that tumour-suppressor genes, such as TP53, retinoblastomaassociated gene 1 (RB1), phosphatase and tensin homologue (PTEN), and CDKN2A (which encodes ARF), can influence immune responses as part of their tumour-suppressor activities [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] (TABLE 1) . In recent years, p53 has been implicated in immune responses and inflammatory diseases 26, 29, 30, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] . Moreover, a novel connection between p53 tumour suppression and enhanced immune response has been proposed recently; p53 was shown to influence the innate immune system by modulating macrophage function via a non-cellautonomous mechanism to suppress tumorigenesis [52] [53] [54] . In this Review, we discuss the latest insights into the role of tumour-suppressor genes in the control of immune responses to infection, autoimmunity and cancer.
The role of p53 in immunity
The p53 tumour suppressor is a master regulatory transcription factor that is activated in response to various cellular stresses; it governs multiple core programmes in cells, including cell cycle arrest, apoptosis, senescence, fertility and metabolism receptor (IFNAR) signalling 43, 45 , suggesting a positive feedback loop involving p53-mediated enrichment of type I IFN signals to improve antiviral immune responses (FIG. 1) . Upon viral infection, the major defensive strategy employed by the host immune system is the activation of the IFN-mediated immune responses. Cells that conserve wild-type p53 functions show an increase in p53-dependent apoptosis in response to viral infection in primary human cells, and p53-deficient mice are more permissive to viral infection, which is probably due to the lack of a p53-dependent apoptotic response 56, 57 . In addition, lack of p53 in mice impaired both innate and adaptive immunity to influenza A virus 58 . It is also known that p53 directly activates expression of immune response genes, including CC-chemokine ligand 2 (CCL2; also known as MCP1), IFN regulatory factor 5 (IRF5), IRF9, protein kinase RNA-activated (PKR), Toll-like receptor 3 (TLR3) and IFN-stimulated gene 15 (ISG15) that are central in initiation of antiviral responses 42, 46, 59, 60 . In fact, many viruses, including SV40, human papillomavirus, Kaposi sarcoma-associated herpes virus, and adenovirus, as well as RNA viruses such as polioviruses, have evolved mechanisms that abrogate p53-mediated responses 61, 62 .
Genes of the TLR family have been identified as direct p53 targets in humans but not in rodents 44, 46 . TLRs are expressed in several types of human immune cells including splenocytes, B cells and T cells, dendritic cells (DCs) and macrophages 44, 46 . The TLRs are membrane glycoproteins that recognize a variety of distinct pathogen-associated molecules [63] [64] [65] . Deregulated expression and activity of TLRs are associated with autoimmune and chronic inflammatory diseases, including systemic lupus erythematosus (SLE), inflammatory bowel disease, type 1 diabetes, multiple sclerosis and rheumatoid arthritis 64, 65 . Therefore, p53-dependent upregulation of TLR expression may contribute to enhanced innate immune responses, although such functional links remain to be further investigated.
p53 can also activate an antitumour immune response via direct transcriptional regulation of the natural killer (NK) cell ligands UL16-binding protein 1 (ULBP1) and ULBP2 in human cancer cells 66 , leading to enhanced killing of tumour cells by NK cells. CD43 (also known as leukosialin) is a cell-surface antigen expressed by most haematopoietic cells; it is an important regulator of immune cell function and is involved in regulation of cell adhesion and proliferation 67, 68 . In humans, 
Immune checkpoint pathways
Immune checkpoints are used by the host to regulate immune responses and prevent immune hyperactivation from harming normal tissues.
overexpression of CD43 in non-haematopoietic cells activates the ARF-p53 tumour suppressor pathway and leads to apoptosis 69, 70 . However, p53 specifically downregulates the expression of CD43 at the mRNA and protein level in non-haematopoietic cells, suggesting a negative feedback loop between p53 and CD43 (REFS 69, 70) . p53 in autoimmunity. Autoimmune diseases are broadly characterized by increased levels of autoreactive T cells and B cells and seem to involve adaptive immune responses targeting self-antigens. In recent years, evidence has emerged that dysfunction of the tumoursuppressor p53 is associated with the development of autoimmune diseases, strongly suggesting that p53 has a protective role by suppressing inappropriate expression of pro-inflammatory factors 51, [71] [72] [73] [74] [75] . Elevated levels of p53 and missense TP53 mutations (codons 213 and 239) have been reported in samples from patients with rheumatoid arthritis and are associated with increased production of interleukin-6 (IL-6) 76 . Defective p53 functions also have been linked to the development of SLE 77 . Serum antibodies to p53 have been reported in patients with SLE, Graves disease, granulomatosis and autoimmune hepatitis [77] [78] [79] [80] [81] . In addition, a number of studies have shown that p53 deficiency is associated with the development of autoimmune and inflammatory diseases in mice [65] [66] [67] [68] [69] . Furthermore, mice lacking Cdkn1a (which encodes p21) or Gadd45, which are two major target genes of p53, develop autoimmune disorders similar to SLE [82] [83] [84] .
In other studies, p53 has been reported to inhibit signal transducer and activator of transcription 1 (STAT1), a transcription factor that drives the expression of IFN-inducible genes and pro-inflammatory cytokines [85] [86] [87] . p53 can also directly repress the activation of the IL6 promoter and nuclear factor-κB (NF-κΒ)-dependent promoters and inhibit the transcription of a set of tumour necrosis factor (TNF)-inducible genes [88] [89] [90] . p53 deficiency in macrophages enhances the production of pro-inflammatory cytokines such as IL-1, IL-6, IL-12 and TNF 91, 92 , which are targets of NF-κΒ and have been implicated in the development of autoimmune diseases 51, 74, 93, 94 . Therefore, it is conceivable that impaired p53 expression contributes to autoimmunity through the excessive production of these cytokines by immune cells.
A potentially distinctive mechanism through which p53 suppresses autoimmunity may involve p53-mediated transcription of forkhead box P3 (Foxp3) in regulatory T (T reg ) cells. It was reported that T cell receptor (TCR) signalling induces p53 expression, and p53 subsequently activates the transcription of Foxp3 by directly binding to its promoter, which contributes to p53-mediated T reg cell induction in mice 48, 50, 93 . Thus, proper expression of p53 in T cells could be crucial in the control of autoimmunity. If so, p53-targeted therapeutics involving small molecule p53 activators, such as Nutlin-3, may be a potential strategy for intervening in autoimmune diseases.
Dead cell clearance and p53. Programmed cell death in the form of apoptosis occurs throughout life in all tissues of the body, and more than a billion cells die in this way every day as part of normal processes. Thus, rapid and efficient clearance of cell corpses is a vital pre requisite for homeostatic maintenance of tissue health [95] [96] [97] [98] [99] . Failure to clear dying cells can lead to the accumulation of autoantigens in tissues that foster diseases such as chronic inflammatory diseases, cancer, autoimmune diseases and developmental abnormalities [95] [96] [97] [98] [99] [100] [101] [102] . In the normal immune system, phagocytic engulfment of apoptotic cells is accompanied by a certain degree of immune tolerance through the activation of immune checkpoint pathways in order to prevent selfantigen recognition [95] [96] [97] [98] [99] . Engulfment of apoptotic cells is an active process coordinated by receptors on phagocytes and ligands on apoptotic cells [100] [101] [102] [103] [104] [105] . Therefore, a better understanding of the homeostatic removal of apoptotic cells could have substantial implications concerning the basic physiology of cell fate, immunotolerance and host response to infection.
It is well established that p53 is an important regulator of apoptosis, and numerous p53 pro-apoptotic target genes have been identified and implicated in apoptosis cascades 17, 20, [106] [107] [108] . However, the postapoptotic involvement of p53 has only lately been identified 109, 110 . We recently reported that p53 controls phagocytosis-mediated clearance of dead cells by inducing the expression of the immunoglobulin superfamily member DD1α 109 (also known as VISTA, PD1H and Gi24 ). This suggests that p53 promotes both pro-apoptotic pathway and post-apoptotic events 109 . Such mice are indistinguishable in appearance from wild-type littermates at an early age. However, from around 10 months of age, DD1α-deficiency results in the development of immune infiltrates in the skin, lung and kidney, implying that immune dysregulation and failure of self-tolerance occur. These findings suggest that p53-mediated induction of DD1α promotes efficient clearance of apoptotic cells and guards against systemic autoimmune diseases, including ulcerative dermatitis, seizures, otitis, eye lesions and glomerulonephritis 109, 110 .
The classical and most well-studied 'eat-me' signal for clearance of apoptotic cells is the phosphatidylserine pathway 100, 103, 104 . Phosphatidylserine, which is sequestered on the inner leaflet of the plasma membrane, becomes exposed on the outer leaflet of the plasma membrane during apoptosis, where it can interact with phosphatidylserine receptors on phagocytes and enable the engulfment of the dying cells 100, 103, 104, 108 . Unlike typical phosphatidylserine scavenger receptors, such as brain angiogenesis inhibitor 1 (BAI1), T cell immunoglobulin and mucin domain-containing protein 4 (TIM4) and MERTK (encoded by MER), DD1α on the surface of dying cells as well as on macrophages can engage in homophilic interactions, which facilitate the recognition, engulfment and clearance of dying cells by macrophages 109 . Thus, p53-dependent stress-mediated activation of DD1α promotes the phagocytic engulfment of dead cells and may assist in the step-wise priming of immune surveillance.
Immune checkpoint regulation and p53. With the exception of virus-induced tumours, cancer cells originate from normal host cells that have acquired genetic alterations that prompt their malignant transformation. Therefore, cancer cells have been thought to be essentially viewed as 'self ' by the host immune system. However, recent evidence indicates that cancer cells may become immunogenic owing to the accumulation of genetically altered proteins termed 'neo-antigens' . Cancer cells exploit various immune escape mechanisms to persist despite chemotherapy and radiotherapy. In fact, tumours can upregulate inhibitory receptors (known as immune checkpoint molecules), such as cytotoxic T lymphocyte antigen 4 (CTLA4) and programmed cell death 1 ligand 1 (PDL1) [115] [116] [117] [118] [119] [120] . These immune checkpoint molecules are important for the induction and maintenance of T cell tolerance [115] [116] [117] [118] [119] [120] [121] [122] . Recent preclinical and clinical studies have indicated that combining chemotherapy or radiotherapy with immune checkpoint inhibitors, such as antibodies specific for PDL1, leads to synergistically enhanced antitumour immune responses that are associated with positive immunomodulatory effects, such as reduced numbers of T reg cells and enhanced frequencies of circulating monocytes and DCs 123 . Several newer immune checkpoint proteins, such as B and T lymphocyte attenuator (BTLA) 121 , TIM3 (REF. 124 ), DD1α [109] [110] [111] 114 and lymphocyte activation gene 3 protein (LAG3) 125, 126 , have also been identified.
A link between p53 and immune checkpoint regulators has been reported in that cancer cells respond to genotoxic stress and DNA damage by upregulating PD1 and its ligand PDL1 in a p53-dependent manner 109 . Moreover, another immune checkpoint regulator DD1α is a direct transcriptional target of p53 (REFS 109, 110, 114) . A number of p53-regulated microRNAs (miRs) have also been implicated in adaptive and innate immunity, including the miR-17-92 cluster 127 , miR-145 and let-7 (REFS 128, 129) . p53 regulates the expression of miR-34, which directly binds to the 3′ untranslated region of the gene encoding PDL1, suggesting that p53 specifically modulates the tumour immune response by regulating PDL1 expression via miR-34 (REF. 130 ). p53 functions in innate and adaptive immunity Role of p53 in DC function. The reported roles of p53 as an important modulator of TLR function, cytokine production and expression of T cell co-inhibitory molecules has prompted investigations on the role of this tumour suppressor in the DC-T cell immune synapse. The nature of the interaction between DCs and T cells, involving MHC-peptide-TCR interactions, as well as a myriad of other pathways regulating immunity and tolerance, regulates T cell fate and is an important target for therapies aimed at harnessing immune responses. As we will discuss, p53 as well as other tumour suppressors have important roles in controlling the microenvironment of the immune synapse (FIG. 2) .
DCs are myeloid cells that are present in both lymphoid and peripheral tissues and have a high capacity for pathogen detection. Importantly, DCs are the only antigen-presenting cells capable of transporting antigen from the periphery to the lymphoid tissues, where they encounter and activate cognate naive T cells 131 . In order to prime T cells, DCs need to undergo a process termed 'maturation' or, perhaps more accurately, 'activation' in vivo. This process involves cytoskeletal rearrangements, loss of phagocytic capacity and increased surface expression of T cell co-stimulatory molecules, such as CD40, CD86, CD80 and MHC proteins 131, 132 .
Owing to their unique role as linkers of innate and adaptive immunity, DCs have a chief role in host immune responses to viruses, especially to those that use epithelial and mucosal surfaces for entry. Although no studies have directly addressed the role of p53 in DC functions, an important body of work indicates that p53 signalling is necessary for proper DC function. For example, p53-dependent cytokine production was shown to be necessary for the recruitment of bloodborne inflammatory monocytes to the sites of influenza virus replication in mice 58 , where they differentiated into monocyte-derived DCs (moDCs). As moDCs are major depots of influenza virus-derived antigens in the respiratory tract 133 , these findings may have implications in antigen storage during influenza virus infection. Moreover, treatment with Nutlin-3 (which blocks the interaction between p53 and its negative regulator MDM2) enhanced the ability of DCs to induce T cell proliferation in a mixed-leukocyte reaction, suggesting that p53 participates in the maturation and/or activation of DCs 134 .
Another link between p53 and DC function is the reported ability of p53 to enhance the expression of MHC class I molecules 135, 136 (FIG. 2) . It is likely that this would enhance the induction of cytotoxic CD8 + T cells that are specific for viruses or other intracellular pathogens, and it will be interesting to assess whether p53 signalling plays a direct part in DC antigen presentation. Pointing in this direction, p53 has been shown to enhance exosome production and secretion 137 . Exosome production by activated DCs is a mechanism for exchange of MHC molecules between antigen presenting cells, presumably to enhance the antigen presentation capability of the host 138, 139 . p53 regulation of cytokine production. Takaoka and colleagues identified p53 as a transcriptional target of type I IFN signalling 45 . More recent studies identified a positive feedback loop between p53 and IFN expression during the antiviral response, due to the ability of p53 to directly transactivate IRF9 -a key component of the IFN signalling pathway 43 . These studies, complement previous evidence that p53 inhibited replication of some viruses in vitro owing to its ability to induce apoptosis [56] [57] [58] 140 and strongly suggest that p53 helps to enforce antiviral responses independently of its functions as a tumour-suppressor gene. In fact, p53 drives the transcriptional activation of other antiviral genes, including TLR3 and IRF5 (REFS 42, 46) . This activation of innate immune signalling by p53 has been shown to lead to production of several cytokines and chemo kines including IFNα and IFNβ 43, 59 , CCL2 and CXC-chemokine ligand 10 (CXCL10; also known as IP10) 60 . Thus, p53 plays an important role in enforcing cytokine production in response to viral infection, as well as in response to other types of cellular stress. p53-dependent expression of IL-15 and CCL2 has also been shown to be necessary to attract NK cells, macrophages and neutrophils for elimination of senescent cells in vivo 60 . Furthermore, it was shown that p53 has an unexpected role in preventing CD4 + T cell proliferation in response to IL-2 alone in the 
Congenital retinoblastoma
Congenital retinoblastoma is the most common eye tumour in children and the third most common cancer overall affecting children; it is caused by a germline mutation in RB1.
absence of antigen-specific TCR signals, which could be limiting bystander proliferation of nonspecific T cells 33 . A link was identified between p53-induced cytokines and the clearance of virus-infected cells in vivo with regards to influenza virus infection in the lung. Specifically, p53-deficient mice failed to produce early pro-inflammatory mediators, such as CXCL10 and CCL2, which resulted in defective DC migration and impaired recruitment of activated monocytes to infected lungs, leading to poor clearance of influenza virus 60 . Perhaps counter-intuitively, p53 has also been shown to antagonize inflammation through inhibition of NF-κB function 92, 141 ; this was shown to result in increased mortality of p53-deficient mice during experimental bacterial infection 142 . However, under other physio logical conditions, p53 cooperates with NF-κB -for example, in the transactivation of genes that contain both NF-κB-and p53-binding sites in their promoters 143 . Such genes include intracellular adhesion molecule 1 (ICAM1) 144 , which is an important modulator of immunity. It is therefore plausible that the cell-fate decisions influenced by p53 in response to infection by different agents may depend on the cytokine context and/or micro environment. Further studies are needed to dissect the mech anisms responsible for p53 activation by innate immunity stimuli and to further define the role of p53 in response to intracellular and extracellular pathogens.
Immune roles of other tumour suppressors
A growing body of evidence indicates that tumour suppressors in addition to p53 have key roles in the modulation of the innate immune system. A clear function in antiviral defence has been reported for the tumour suppressors RB1, ARF and PTEN 43, 45, [145] [146] [147] . Activation of the genes encoding these tumour-suppressors has been described after IFN treatment, following the expression of viral proteins and during viral infection. Mice lacking several prominent tumour-suppressor genes, including Tp53, Rb1, Cdkn2a and Pten, have been demonstrated to be more susceptible to chronic inflammatory responses triggered by pathogens and environmental stress 43, [145] [146] [147] . Below, we discuss the immunological roles that have been described for tumour-suppressor proteins other than p53.
Role of RB1 in immune cell differentiation and immune evasion. The loss of function of RB1 was first identified as responsible for initiating congenital retinoblastoma 31, 148 . Subsequently, it became apparent that functional inactivation of the RB1 pathway is a common event in most human malignancies 31, [148] [149] [150] [151] [152] . RB1 directly binds to members of the E2F family of transcription factors 31, 151 , which play a major part in the regulation of cell proliferation, and differentiation 153, 154 . An increasing body of evidence indicates that the tumour suppressor RB1 is also involved in immune functions 155 , and the expression of a large subset of immune genes is downregulated following RB1 loss 150, 155 . These genes include those encoding immune cell surface receptors, complement components, and cytokines 150, 155 (FIG. 2) . RB1 deficiency in mice also results in increased susceptibility to viral infection, decreased TLR3 expression, reduced nuclear localization of the RELA (also known as p65) subunit of NF-κΒ and diminished production of cytokines and chemokines, including IFNβ and IL-8 (REFS 146, 150, 156) . Moreover, RB1 is frequently downregulated by oncogenic viral proteins during viral infection in mouse cells 146, [157] [158] [159] . PTEN tumour suppressor in T cell regulation. The phosphatidylinositol 3-kinase (PI3K) signalling pathway is one of the major pathways activated upon TCR, IL-2R, and CD28 stimulation, leading to T cell activation, proliferation, and cell survival 160, 161 . This pathway is negatively regulated by the tumour suppressor PTEN -a lipid phosphatase 25 that is frequently inactivated in a variety of human cancers 23, 25 . Mice with a T cell-specific deficiency in PTEN activation have defects in central and peripheral tolerance and show increased susceptibility to T cell lymphoma and leukaemia [162] [163] [164] [165] [166] . Mice that are heterozygous for PTEN also develop lethal autoimmune diseases with splenomegaly, lymphadenopathy, inflammatory infiltration in many organs and glomerulopathy resembling that seen in autoimmune-prone mouse strains [166] [167] [168] . In the context of T cell function, PTEN influences T cell differentiation and polarization towards T helper (T H ) cell phenotypes in mice 169 . This is likely to be partially due to important functions of PTEN in DC maturation (FIG. 2) . During T H cell induction, PTEN function is suppressed whereas the level of PTEN transcripts is increased during the formation of peripheral FOXP3 + T reg cells 169 . In patients, loss of PTEN significantly correlates with diminished T cell infiltration at tumour sites, reduced chance of successful T cell growth from resected tumours and a poorer response to PD1 blockade therapy. This suggests that combinatorial strategies that target the PI3K-AKT pathway may enhance the efficacy of immunotherapy 170 . Although mechanistically not fully understood, these findings strongly suggest that PTEN is directly involved in T cell fate.
ARF tumour suppressor as a regulator of inflammation and macrophage activation. The alternative reading frame (ARF) is, together with p16, one of two tumour suppressors encoded by the INK4a-ARF locus -a frequently mutated locus in human cancer 171, 172 . p16-INK4a and ARF respectively regulate the activity of RB1 and p53 . ARF was initially discovered as a cellular protein upregulated following oncogenic stress, and it was later linked to p53 stabilization 63, 172, 173 . ARF also inhibits the cell cycle, promotes cellular senescence and has been linked to cancer and ageing [171] [172] [173] [174] [175] . In addition, ARF acts as a general sensor for cellular stress. ARF deficiency in mice has been reported to aggravate athero sclerosis through the reduction of macrophage and vascular smooth muscle cell apoptosis 176, 177 . ARF is activated in response to the expression of viral proteins, viral infection or type I IFN treatment in human cells 145, 178, 179 . ARF seems to be a crucial modulator of the inflammatory response and macrophage activation. Mice lacking the gene that encodes ARF are resistant to lipopolysaccharide (LPS)-induced endotoxic shock and show a significant reduction of leukocyte recruitment 176, 180 . In addition, ARF deficiency can lead 179 or virus infection 145 . However, owing to the well-known link between ARF and p53, it was only recently that ARF was hypothesized to drive p53-independent functions during virus infection. To date, ARF has been demonstrated to have an antiviral role against DNA viruses with oncogenic properties, such as human papilloma virus (HPV) and simian virus 40 (SV40), and (similarly to p53) against non-oncogenic RNA viruses, such as vesicular stomatitis virus (VSV), Sindbis virus and an engineered IFN-sensitive recombinant vaccinia virus strain 145 . Again, resembling the antiviral functions of p53, ARF is activated via IRF3 response elements in its promoter 179 and provides a positive feedback loop in the IFN-mediated antiviral response through direct activation of protein kinase R (PKR) 145 . Perhaps linked to its activation of PKR or other IFN-induced genes, a role of ARF in the regulation of cytokine production in mice in response to LPS and other pro-inflammatory stimuli has also been described 180 .
The role of BRCA1 and BRAC2 in the immune response. The breast cancer type 1 susceptibility (BRCA1) and breast cancer type 2 susceptibility (BRCA2) genes are associated with familial breast cancer and ovarian cancer [181] [182] [183] [184] . Individuals who inherit germline mutations in these genes have a high lifetime risk of developing breast and ovarian cancers. The BRCA genes have been implicated in the regulation of a number of cellular functions, including DNA damage responses, DNA repair and replication, cell cycle regulation, ubiquity lation and transcriptional regulation 181, 184 . Recently, genes were identified that are regulated by BRCA1 in the presence of IFNγ, but not in the presence of IFNα or IFNβ 185 . These genes included those involved in the induction of STAT1, STAT2 and type 1 IFNs in response to IFNγ, suggesting that BRCA1 and IFNγ cooperate to activate a subset of innate immune response genes. Moreover, combined treatment using a poly (ADP-ribose) polymerase 1 (PARP1) inhibitor together with CTLA4 checkpoint blockade increased long-term survival in a BRCA1-deficient mouse ovarian tumour model 186 . A heterozygous germline Brca2 mutation was associated with immune dysfunction in mice, and mature naive T cell populations were highly susceptible to death caused by BRCA2 deficiency 187 . A large, populationbased study with intermediate-risk of ovarian cancer observed a significant association between intraepithelial tumour-infiltrating lymphocytes and BRCA1 and/or BRCA2 mutation or epigenetic loss 188 . Although the tumour-suppressor genes are clearly involved in crucial aspects of tumour immunology and in homeostatic regulation of immune responses, accumulating recent evidence strongly suggests that differential activation of specific oncogene pathways, such as β-catenin and MYC, promotes immune exclusion in a subset of cancers [189] [190] [191] . Thus, further understanding Owing to its roles in inducing cell cycle arrest and apoptosis in stressed cells, p53 has been referred to as the 'guardian of the genome'. More recently, it has become apparent that p53 has important roles in promoting immune tolerance. p53 induces the expression of immune checkpoint molecules such as programmed cell death 1 (PD1), PD1 ligand 1 (PDL1) and DD1α, which negatively regulate effector T cell responses. Furthermore, p53 enhances the detection and uptake of apoptotic cells by the immune system. As such, we suggest that p53 can also be considered as a guardian of immune integrity.
of the molecular mechanisms underlying the oncogenic signalling-mediated immune evasion may lead to the identification of new therapeutic targets and/or approaches for escalating efficacy of immunotherapies.
Conclusion
The discovery of new tumour-suppressor genes and improved insight into the biology of these genes has led to a better understanding of the pathophysiological roles of tumour suppressors in both healthy and cancerous cells. The crucial roles of these genes in suppressing malignancy have led to wide-ranging investigations into the mechanisms of their actions at the molecular, cellular and organismal levels. Most studies have focused on determining the pathways involved in cell cycle arrest, apoptosis or DNA-damage response signalling. More recently, ample evidence has pointed to a potential link between tumour suppressors, such as p53, and immune function, and tumour-suppressor genes have also been implicated in inflammatory diseases. Accumulating evidence suggests that tumour suppressor genes may negatively regulate immune responses, as highlighted by the numerous alterations or phenotypic dysfunctions that have been observed in cells and mice deficient in these genes. It is not surprising that recently discovered physiological activities of p53 involve homeostatic stress responses involved in main tenance of key processes that help to prevent unnecessary inflammation and sustain self-tolerance mechanisms. Therefore, p53 not only keeps cellular proliferation in check through the activation of cell cycle checkpoint regulators but also keeps immune responses in check through the activation of immune checkpoint inhibitors (FIG. 3) . Thus, the coordi nated induction of multiple p53 immune checkpoint targets may explain why the absence of p53 predisposes mice to autoimmune diseases.
p53 has a well-established function as the 'guardian of genome integrity' . However, it has also been implicated in a growing number of homeostatic stress responses, including in aspects of innate and adaptive immunity, as described above. These studies are still at a relatively early stage, but it is possible that p53 may eventually come to be regarded as a 'guardian of immune integrity' . Notably, accumulating evidence indicates that other tumour-suppressor genes may have similar functions. 
